Post-translational regulation of NLRP3 inflammasome in Tet2-/- clonal hematopoiesis and atherosclerosis
Description: Clonal hematopoiesis (CH) has been identified as a major independent risk factor for cardiovascular disease (CVD), with an impact comparable to traditional risk factors. Myeloid cell inflammatory processes including inflammasome activation have been discovered as underlying mechanisms of accelerated atherosclerosis, especially in Tet2 CH. These discoveries dovetail with clinical trials showing reduced CVD in response to suppression of inflammasomes or their products, suggesting a precision approach to reducing CVD risk in CH. However, new approaches to anti-inflammatory treatments are needed. Recently, we discovered that a novel activating pathway involving JNK1-mediated phosphorylation and deubiquitylation of NLRP3 by BRCC3, is increased in TET2 deficient macrophages, promoting atherosclerosis. In cell culture studies, the mechanism of JNK activation in TET2 deficient macrophages was increased promoter methylation and decreased expression of the JNK-inactivating dual specificity phosphatase, Dusp10. However, the in vivo significance of Dusp10 has not been tested. Our results also showed that hypercholesterolemia and TET2 deficiency act synergistically to activate the NLRP3 inflammasome, which suggests the importance of control of hypercholesterolemia in TET2 CH. Aim 1 will assess the impact of cholesterol lowering in TET2 CH lesions in an atherosclerosis regression study to test the hypothesis that cholesterol lowering will reverse inflammasome activation in TET2 CH causing regression similar to controls. Aim 2 will investigate the in vivo role of Dusp10 promoter methylation in promoting NLRP3 inflammasome activation in Tet2 CH mice by lentiviral restoration of DUSP10 expression in Tet2-/- long-term hematopoietic stem cells followed by transplantation in Ldlr-/- mice. I will also use novel methods that employ dCas9 fused to Tet1 to mediate targeted DNA demethylation of the Dusp10 promoter, as a way to assess the impact of specific gene promoter methylation on inflammasome activation and atherogenesis. During the award phase, I will continue to gain expertise in macrophage inflammatory processes and epigenomic changes in atherosclerosis. An advisory committee of scientists and collaborators with expertise in these areas and excellent mentorship qualifications will guide me in the steps toward a successful transition to scientific independence over the course of the award period.
Funder: American Heart Association
Amount: $231,000
Funding type: fellowship
Funder scheme: Career Development Award
Start date: 2024-04-01
End date: 2027-03-31
Investigator: Mustafa Yalcinkaya (lead)
Institutions: Columbia University, The Trustees of Columbia University in the City of New York
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 2
Funder award ID: 24CDA1275172
OpenAlex ID: G148611876
